OncologyBristol Myers Squibb
Bristol Myers Squibb Reports Positive CheckMate-9DW Results for Opdivo in Liver Cancer
BMI
Biotechnology Media Insights
Editorial Team · September 22, 2025
BMS announces positive Phase 3 CheckMate-9DW trial results showing nivolumab plus ipilimumab improves overall survival in first-line hepatocellular carcinoma.
Bristol Myers Squibb today announced positive results from the Phase 3 CheckMate-9DW trial evaluating nivolumab plus ipilimumab versus sorafenib or lenvatinib in patients with previously untreated unresectable hepatocellular carcinoma (HCC). The combination reduced the risk of death by 21% compared to sorafenib or lenvatinib.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.